Articles - FCS Hematology Oncology Review

Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?

June 1, 2022

Very interesting study. High-risk histology and lymphovascular invasion which are relatively common will be good markers for adjuvant chemotherapy. Morbidity and complications for RPLND may be higher in lower volume centers. At least this study brings further data for patients who are unwilling or severely concerned about receiving chemotherapy.

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

June 1, 2022

Excellent study demonstrating the value of evaluation of ctDNA/molecular disease and impact of adjuvant chemotherapy. Guidelines will change rather significantly (for different cancers) in this decade, as to who actually needs post-operative chemotherapy. More prolonged follow-up is warranted.

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)

May 1, 2022

Lots of progress to be accomplished here. Increased standardization of care, quality metrics based on guideline-adherence and best practices remain critical to progress.

Teclistamab in Relapsed or Refractory Multiple Myeloma

May 1, 2022

The Bi-specific antibody era has started full-force with impressive results and reasonable toxicities, in different hematological neoplasms. Community oncology adoption of Bi-specific antibody will be successful, once standard operating procedures are in place, and multidisciplinary training takes place insofar as management of CRS. I am optimistic as to the uptake of this class of drugs in 1-2 years, pending payer coverage issues.

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS^G12C Mutation

May 1, 2022

It is always desirable to have more options in this space, KRAS G12c mutated NSCLC lung patients. A median duration of response above 8 months is rather exciting in this setting. Detection of such patients who may be candidates for such therapy is of critical importance.

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

May 1, 2022

Important clinical trial update with more mature data. Risk of death is 34% lower in combined enzalutamide and LHRH analog versus the latter alone.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

May 1, 2022

This is a potential practice-changing study. Future data on overall-survival (OS) will be important to confirm results. Patient selection will also evolve over time especially in real-world practice. I presume more patients with stage II/III will get neoadjuvant therapy as opposed to a patient with a small lung nodule (stage I) taken to surgery, unless if there is significant OS for early stage patients as well.

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

May 1, 2022

This study is as exciting as it gets in terms of innovation and impact in a large population of metastatic breast cancer, low HER2 expressors. Rapid identification of such patients is of critical importance given the superiority to standard chemotherapy agents.

Mitapivat versus Placebo for Pyruvate Kinase Deficiency

April 1, 2022

Rare disease process that can carry significant morbidity. It is encouraging to see 40% response in such patient population when no other therapies (this is a first-in class) exist besides supportive care with very favorable toxicity profile.

Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia

April 1, 2022

Interesting drug and mechanism of action in the setting of ITP. Tolerability, efficacy appeared promising. Larger studies and post-marketing RWE will be of help in analyzing this treatment option.

Article Search

Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)

Teclistamab in Relapsed or Refractory Multiple Myeloma

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS^G12C Mutation

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Mitapivat versus Placebo for Pyruvate Kinase Deficiency

Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia

Keyword Search

Article Search

Cancer Types

Month Contributed

Show FCS Articles Only

Sort Order

Number of Posts

Menu

About This Site